IntelGenx gets green light to launch Ph2 Alzheimer’s study in Canada

IntelGenx (CVE:IGX) said today that Health Canada approved its application to study its montelukast VersaFilm therapy in adults with mild to moderate Alzheimer’s disease.

The Phase IIa proof-of-concept trial is slated to begin screening patients in the first quarter of next year.

Get the full story at our sister site, Drug Delivery Business News.

The post IntelGenx gets green light to launch Ph2 Alzheimer’s study in Canada appeared first on MassDevice.

from MassDevice http://ift.tt/2ohNeCr